Efficacy Outcomes in the Phase 3 COMBI-AD Study of Adjuvant Dabrafenib Plus Trametinib vs Placebo in Patients with Stage III BRAFV600E/K-Mutant Melanoma. (2018). SKIN The Journal of Cutaneous Medicine, 2(S1), S43. https://doi.org/10.25251/skin.2.supp.43